In this study, the authors' experience of Parkinson Disease treatment with longterm bromocriptine (Br) administration, is summarized. Br, which acts directly on dopaminergic receptors, was introduced in combination with L-Dopa and peripheral decarboxylase inhibitors (PDI). The reasons for this association were: the reduced effectiveness of the current treatment (L-Dopa+PDI), onset of AIM (abnormal involuntary movements), and the patient's desire to try new drugs. Only the patients who had been on the triple association for at least a year were considered. Therefore, of 50 patients originally considered, only 19 were included in this study. The addition of Br allowed a reduction of the mean daily dose of L-Dopa (30%) and the therapeutic efficacy of the drug remained unchanged even after more than 4 years treatment. The 'on-off' effect and AIM, are reduced by Br, especially in the first months of treatment. The triple association is regarded at present as the best treatment for Parkinson disease.
|Number of pages||6|
|Journal||Italian Journal of Neurological Sciences|
|Publication status||Published - 1981|
ASJC Scopus subject areas
- Clinical Neurology